Eden Research plc - Trading Update
The information contained within this announcement is deemed to constitute inside information as stipulated under the retained EU law version of the Market Abuse Regulation (EU) No. 596/2014 (the "

Eden Research
("Eden" or "the Company")
Trading Update
Eden Research plc (AIM: EDEN), a leader in sustainable biopesticide and biocontrol technology, provides the following unaudited trading update.
Overview
As announced in the Half-Yearly Report on
· Revenue is expected to be c.
· PBT is expected to be c.
· Cash at period end of
"We confirm that we expect to be broadly in line with market expectations for revenue and PBT for the period to
The last fifteen months have been a highly productive period for Eden, and it is clear that we are on a path to success with the products we have in the market and with those we are developing in-house. There is strong interest in our existing and developmental products, driven by our ongoing marketing efforts and the industry's transition towards sustainable solutions, which is both rewarding and encouraging.
I look forward to updating shareholders in due course with further news pertaining to our upcoming milestones and exciting developments in our development pipeline."
Highlights
From
Major 2025-26 regulatory milestones
Mevalone
- Mevalone gained approval in the US state of
- Mevalone received a major label extension in
Ecovelex and other products
- Ecovelex 2025 obtained its third temporary authorisation in
- Regulatory progress continued on Eden's broader biofungicide and biocontrol portfolio in
Commercial partnerships and distribution
Syngenta distribution agreement (
- Eden entered into an exclusive distribution agreement with Syngenta Crop Protection AG for a novel fungicide product in the high-value ornamentals market, an as-yet untapped opportunity for Eden's fungicide products in
- The deal brings another major global partner onto the Company's list of commercial partners and is expected to expand geographic reach, accelerate market penetration and validate Eden's terpene‑based technology with yet another leading global agrochemical company.
New territories and channels
- Eden appointed a new distribution partner in
- In appointing Andermatt, Eden has further executed on its strategy to simplify the value chain wherever possible, moving closer to the grower in order to build reputation and maximise margin opportunities.
- Additional distribution arrangements and organic input registrations (for example, in
Data access agreement
- The Company signed a data access agreement with TerpeneTech Limited ("TerpeneTech"), Eden's associate company, to provide it with access to the Company's Dossier Data on Geraniol that will enable TerpeneTech to continue in its capacity as a notified supplier of Geraniol under the EU's Biocidal Products Regulations. Under the terms of the agreement, a fee of
- Eden continues to leverage its investment in both regulatory authorisations and the data that underpins these authorisations. More recent deals not only include this latest transaction with TerpeneTech, but also the sale of thymol to Véto-pharma in conjuction with regulatory data access in
Fundraise
On
The firm placing, subscription and retail offer admitted on
The Company will use the funds to develop and register an additional fungicide for late blight, which has shown encouraging efficacy, as well as to register and begin commercialisation of its insecticide targeting spider mites, whitefly, aphids and thrips. The funds will also allow for the development of a broad acre crop fungicide for Septoria in wheat and to continue to drive commercial progress on the back of recent approvals and expected further overseas approvals.
Key takeaways
Strategic progress
Since
Investment case
The news-flow supports an investment case centred on scaling a differentiated, sustainable biopesticide platform, leveraging strong regional and local partnerships and a growing portfolio of registrations to drive medium and longer term revenue growth and geographic diversification.
Product pipeline
Insecticide
· Eden expects to finalise commercial arrangements for its insecticide product with at least one major crop protection business in H1, 2026.
Ecovelex
· The Company awaits approval from the EU Rapporteur Member State for Ecovelex, which is expected in 2026, with other concerned member states granting approval thereafter.
Fungicide 2
· A number of interested parties have tested Fungicide 2 against late blight on potatoes with positive results. The Company expects to enter into commercial arrangements for this product in H2, 2026/H1, 2027.
Future newsflow
• Commercial /development agreement(s) for insecticide H1, 2026
• Authorisation of Ecovelex in
• Approval of Mevalone in Colombia 2026
• Further removal of US label restrictions 2026
• Commercial agreement(s) for Fungicide 2 (late blight) H2, 2026 / H1, 2027
Outlook
We look forward to announcing the newsflow items listed above, all of which are meaningful to the Company's ongoing commercial progress.
These follow on from the important milestones that have been met over the past year, such as the regulatory approvals in France for downy and powdery mildew and Italy for Ecovelex, as well as new commercial agreements with Andermatt and Syngenta.
We now expect to start to see the benefit of these various milestones through increasing product sales, which will continue to drive us toward profitability.
Moreover, we expect to continue to make significant step-changes to become a significant, independent participant in the crop protection market.
For further information contact:
|
Eden Research plc |
|
|
Sean Smith
|
01285 359 555 |
|
|
|
|
Cavendish Capital Markets Limited (Nominated advisor and joint broker) |
|
|
Giles Balleny / Elysia Bough (Corporate Finance) Harriet Ward (Corporate Broking)
|
020 7220 0500 |
|
|
|
|
Oberon Capital (Joint Broker) |
020 3179 5300 |
|
Nick Lovering Mike Seabrook Adam Pollock
|
|
|
Hawthorn Advisors (Financial PR) |
|
|
Jamie Plotnek
|
|
Notes to Editors:
Eden Research is the only UK-listed company focused on biopesticides for sustainable agriculture. It develops and supplies innovative biopesticide products and natural microencapsulation technologies to the global crop protection, animal health and consumer products industries.
Eden's products are formulated with terpene active ingredients, based on natural plant defence metabolites. To date, they have been primarily used on high-value fruits and vegetables, improving crop yields and marketability, with equal or better performance when compared with conventional pesticides. Eden has three products currently on the market:
Based on plant-derived active ingredients, Mevalone® is a foliar biofungicide which initially targets a key disease affecting grapes and other high-value fruit and vegetable crops. It is a useful tool in crop defence programmes and is aligned with the requirements of integrated pest management programmes. It is approved for sale in a number of key countries whilst Eden and its partners pursue regulatory clearance in new territories thereby growing Eden's addressable market globally.
Cedroz™ is a bionematicide that targets free living nematodes which are parasitic worms that affect a wide range of high-value fruit and vegetable crops globally. Cedroz is registered for sale on two continents and Eden's commercial collaborator, Eastman Chemical, is pursuing registration and commercialisation of this important new product in numerous countries globally.
Eden's seed treatment product, EcovelexÔ was developed to safely tackle crop destruction caused by birds - a major cause of losses in maize and other crops. Ecovelex works by creating an unpleasant taste or odour that repels birds, leaving the seeds safely intact and the birds unaffected and free to find alternative food sources. The product is based on Eden's plant-derived chemistry, registered in the EU, US and elsewhere, and formulated using Eden's Sustaine® microencapsulation system.
Eden's Sustaine® encapsulation technology is used to harness the biocidal efficacy of naturally occurring chemicals produced by plants (terpenes) and can also be used with both natural and synthetic compounds to enhance their performance and ease-of-use. Sustaine microcapsules are naturally-derived, plastic-free, biodegradable micro-spheres derived from yeast. It is one of the only viable, proven and immediately registerable solutions to the microplastics problem in formulations requiring encapsulation.
Eden was admitted to trading on AIM on 11 May 2012 and trades under the symbol EDEN. It was awarded the London Stock Exchange Green Economy Mark in January 2021, which recognises London-listed companies that derive over 50% of their total annual revenue from products and services that contribute to the global green economy. Eden derives 100% of its total annual revenues from sustainable products and services.
For more information about Eden, please visit: www.edenresearch.com.
Follow Eden on LinkedIn, Twitter and YouTube.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.
Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.
This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.
In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.
The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.
Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.
From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.
FOR OUR FULL DISCLAIMER CLICK HERE